Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655033 | 0.80 | ACHE (0.57) | SIGMAR1BCHE | |
| SCHEMBL2165072 | 0.77 | ALDH1A1 (0.47) | CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL2164485 | 0.74 | SMN1; SMN2 (0.41) | HTTSIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2164153 | 0.71 | KDM4E (0.39) | PKMHTTCYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL19770184 | 0.69 | ACHE (0.62) | PKMHTTOPRM1ABL1RIN1 | |
| SCHEMBL7651915 | 0.69 | ACHE (0.62) | PKMHTTOPRM1ABL1RIN1 | |
| SCHEMBL4987941 | 0.67 | ACHE (0.57) | HTTSIGMAR1ALDH1A1BCHE | |
| Hydrochloric Acid SCHEMBL3156656 | 0.67 | ABL1 (0.56) | OPRM1ABL1RIN1SIGMAR1BCHE | |
| SCHEMBL7810400 | 0.67 | ABL1 (0.56) | OPRM1ABL1RIN1SIGMAR1ALDH1A1 | |
| SCHEMBL14636306 | 0.66 | ACHE (0.48) | SIGMAR1ALDH1A1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | PKM 3394/4885HTT 3023/4885OPRM1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.